Prof. Davies talks about the interrelationship between T2DM, CVD (including heart failure) and CKD and how treatment with GLP-1RAs affects these interrelated systems.
Patients with diabetic kidney disease (DKD) have an unmet residual CV risk. Prof. Stroes brings up some novel opportunities to treat this risk and elaborates on mechanisms of CV benefit by GLP-1RAs.
ADA 2020 A prespecified analysis from REDUCE-IT demonstrated that first and total (first plus recurrent) CV events were reduced with icosapent ethyl compared to placebo in patients with diabetes.
ADA 2020 The ATP citrate lyase inhibitor bempedoic acid lowered LDL-c compared to placebo in high-risk CV patients across all glycemic status subgroups, shown by a pooled analysis from four phase 3 trials.
ADA 2020 The SGLT2 inhibitor dapagliflozin reduced risk of new-onset T2DM in HFrEF patients, demonstrated by a prespecified analysis of the DAPA-HF trial.
ERA-EDTA 2020 The initial eGFR dip after initiation of empagliflozin has raised some concerns. A post-hoc analysis was therefore performed to investigate the impact of an eGFR dip.
Members of the Diabetes and Cardiovascular Disease EASD Study Group have published a perspective on issues of CV risk management in diabetes patients during the COVID-19 pandemic.
Administration of 4 g/day icosapent ethyl reduced first coronary revascularizations by 34% compared to placebo in patients with elevated triglyceride levels, who had CVD or diabetes with additional CV risk factors.
A consensus document by a group of representatives from primary and secondary care has been published on the management of diabetes for patients at risk or with confirmed COVID-19.
This study showed that the most frequent first manifestations of CV- and renal disease in T2DM patients were HF and CKD, which were both associated with increased all-cause and CVD mortality risk.
The phase 3 VERTIS CV outcomes trial with the SGLT2 inhibitor ertugliflozin has achieved its primary endpoint of non-inferiority for MACE in T2DM patients with established ASCVD.
ACC 2020 COMPASS Diabetes compared treatment of low-dose rivaroxaban plus aspirin with aspirin alone in stable CAD and/or PAD patients with or without diabetes.